Colorectal Cancer Survivors’ Receptivity toward Genomic Testing and Targeted Use of Non-Steroidal Anti-Inflammatory Drugs to Prevent Cancer Recurrence

O’Malley, Denalee; Blair, Cindy K.; Greenbaum, Alissa; Rajput, Ashwani; Chiu, Vi K.; Kinney, Anita Y.

doi:10.1007/s12687-021-00574-9

Cited by 2 publications

(2 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study revealed genomic testing interest was associated with being uncoupled (odds ratio (OR) = 4.11, 95% confidence interval (CI) = 1.49-11.35), low income (OR = 0.35, 95% CI = 0.14-0.88), smoking history (OR = 0.35, 95% CI = 0.14-0.90), low health literacy (OR = 0.33, 95% CI = 0.07-1.43), moderate health literacy (OR = 0.26, 95% CI = 0.11-0.61), and personal CRC risk worry (OR = 2.86, 95% CI = 1.63-5.02, p = 0.0002). Age (OR = 1.05, 95% CI = 1.01-1.10) and a history of cardiovascular disease (OR = 2.42, 95% CI = 1.23-4.73, p = 0.010) were also related to aspirin use [ 25 ].…”

Section: Reviewmentioning

confidence: 99%

Protective Effects of Long-Term Usage of Cyclo-Oxygenase-2 Inhibitors on Colorectal Cancer in Genetically Predisposed Individuals and Their Overall Effect on Prognosis: A Systematic Review

Narayana,

Mushtaq,

Shaman Ameen

et al. 2023

Cureus

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a major global health concern, accounting for significant cancer-related morbidity and mortality worldwide. Despite advancements in early detection and treatment modalities, the prevention of CRC remains a critical goal. Cyclo-oxygenase-2 (COX-2) is an inducible enzyme involved in the production of pro-inflammatory prostaglandins, which play a crucial role in various cellular processes, including inflammation, cell proliferation, apoptosis, and angiogenesis. Elevated COX-2 expression has been consistently observed in colorectal tumors, indicating their role in the pathogenesis of cancer. COX-2 inhibitors, such as celecoxib and rofecoxib, have been studied as potentially effective treatment modalities due to their ability to decrease prostaglandin levels, which are generally higher in cancer patients. Aberrant prostaglandin production is linked to the adenoma-carcinoma sequence, during which adenomas turn dysplastic and accumulate enough damage to become malignant. COX-2 inhibitors have also been shown to modulate various signaling pathways involved in CRC development, such as wingless-related integration site/β-catenin (Wnt/β-catenin), mitogen-activated protein kinase (MAPK), and phosphoinositide-3-kinaseprotein kinase B/Akt (PI3K/Akt) pathways. This systematic review aimed to evaluate the protective effects of long-term usage of COX-2 inhibitors on CRC in genetically predisposed individuals and their overall effect on the prognosis of the disease. The researchers conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines and collected data from several databases, including PubMed, PubMed Central, Cochrane Library, and Web of Science. The search strategy combined keywords related to CRC, COX-2 inhibitors, protective effects, and prognosis. They identified 1189 articles and shortlisted 26 full-text articles that met the eligibility criteria. Quality assessment tools, such as the Assessment of Multiple Systematic Review (AMSTAR) for systematic reviews, the Cochrane bias assessment tool for randomized control trials, the scale for the assessment of narrative review articles (SANRA) checklist for narrative reviews, and the Joanna Briggs Institute (JBI) tool for crosssectional studies and case reports, are used. This review's conclusions will assist in determining the effectiveness of COX-2 inhibitors to prevent CRC. This review may also contribute to developing guidelines for clinicians to manage genetically predisposed individuals with CRC. Furthermore, the results of this review will shed light on the potential of COX-2 inhibitors as a preventive measure against CRC in genetically predisposed individuals.

show abstract

Section: Reviewmentioning

confidence: 99%

Protective Effects of Long-Term Usage of Cyclo-Oxygenase-2 Inhibitors on Colorectal Cancer in Genetically Predisposed Individuals and Their Overall Effect on Prognosis: A Systematic Review

Narayana,

Mushtaq,

Shaman Ameen

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…In this regard, a number of anti-infammatory medications, including cyclooxygenase 2 inhibitors have been tested for colorectal and chemotherapy-resistant breast cancer [62,63]. Nonsteroidal anti-infammatory drugs are reported for breast, colorectal, and prostate cancer treatment [64]. Anti-infammatory steroid drugs such as dexamethasone used for the treatment of brain tumors, have been found to lower tumor incidence and slow down tumor progression and lower overall mortality rates [65].…”

Section: Targeting Infammation Through Anti-infammatorymentioning

confidence: 99%

Targeting Tumor Microenvironment by Metal Peroxide Nanoparticles in Cancer Therapy

Mbugua

2022

Bioinorganic Chemistry and Applications

View full text Add to dashboard Cite

Solid tumors have a unique tumor microenvironment (TME), which includes hypoxia, low acidity, and high hydrogen peroxide and glutathione (GSH) levels, among others. These unique factors, which offer favourable microenvironments and nourishment for tumor development and spread, also serve as a gateway for specific and successful cancer therapies. A good example is metal peroxide structures which have been synthesized and utilized to enhance oxygen supply and they have shown great promise in the alleviation of hypoxia. In a hypoxic environment, certain oxygen-dependent treatments such as photodynamic therapy and radiotherapy fail to respond and therefore modulating the hypoxic tumor microenvironment has been found to enhance the antitumor impact of certain drugs. Under acidic environments, the hydrogen peroxide produced by the reaction of metal peroxides with water not only induces oxidative stress but also produces additional oxygen. This is achieved since hydrogen peroxide acts as a reactive substrate for molecules such as catalyse enzymes, alleviating tumor hypoxia observed in the tumor microenvironment. Metal ions released in the process can also offer distinct bioactivity in their own right. Metal peroxides used in anticancer therapy are a rapidly evolving field, and there is good evidence that they are a good option for regulating the tumor microenvironment in cancer therapy. In this regard, the synthesis and mechanisms behind the successful application of metal peroxides to specifically target the tumor microenvironment are highlighted in this review. Various characteristics of TME such as angiogenesis, inflammation, hypoxia, acidity levels, and metal ion homeostasis are addressed in this regard, together with certain forms of synergistic combination treatments.

show abstract

Colorectal Cancer Survivors’ Receptivity toward Genomic Testing and Targeted Use of Non-Steroidal Anti-Inflammatory Drugs to Prevent Cancer Recurrence

Cited by 2 publications

References 92 publications

Protective Effects of Long-Term Usage of Cyclo-Oxygenase-2 Inhibitors on Colorectal Cancer in Genetically Predisposed Individuals and Their Overall Effect on Prognosis: A Systematic Review

Protective Effects of Long-Term Usage of Cyclo-Oxygenase-2 Inhibitors on Colorectal Cancer in Genetically Predisposed Individuals and Their Overall Effect on Prognosis: A Systematic Review

Targeting Tumor Microenvironment by Metal Peroxide Nanoparticles in Cancer Therapy

Contact Info

Product

Resources

About